Specifically, amplification of the StAR gene was 26% in a breast cancer patient xenografts study, 12% in breast cancer METABRIC, and 13% and 14% in two independent publications associated with breast invasive carcinomas, and 15% each in two independent metastatic breast cancer studies (specified in Section 2). This evidence concerns the gene STAR and breast carcinoma.